4//SEC Filing
Haas Jason 4
Accession 0000950170-24-120869
CIK 0001556263other
Filed
Nov 3, 7:00 PM ET
Accepted
Nov 4, 5:01 PM ET
Size
8.7 KB
Accession
0000950170-24-120869
Insider Transaction Report
Form 4
Haas Jason
Chief Financial Officer
Transactions
- Tax Payment
Common Stock
2024-10-31$2.09/sh−5,624$11,754→ 137,803 total - Exercise/Conversion
Common Stock
2024-10-31+18,875→ 143,427 total - Exercise/Conversion
Restricted Stock Units
2024-10-31−18,875→ 0 total→ Common Stock (18,875 underlying)
Footnotes (4)
- [F1]Represents shares of common stock received upon vesting of a restricted stock unit award.
- [F2]Represents shares used to cover tax withholding on a restricted stock unit release.
- [F3]Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
- [F4]Represents a restricted stock unit award granted on October 6, 2022. These restricted stock units vested as to one half (50%) of the shares on October 31, 2023, and as to one half (50%) of the shares on October 31, 2024.
Documents
Issuer
Syros Pharmaceuticals, Inc.
CIK 0001556263
Entity typeother
Related Parties
1- filerCIK 0001883821
Filing Metadata
- Form type
- 4
- Filed
- Nov 3, 7:00 PM ET
- Accepted
- Nov 4, 5:01 PM ET
- Size
- 8.7 KB